About

About Illumina, Inc. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. At Illumina, our mission is to improve human health by unlocking the power of the genome. Our sequencing by synthesis chemistry is used to generate high-accuracy DNA and RNA sequence data in studies around the globe. The innovative products that we provide are helping drive advancements in a multiomic understanding of cellular functions, combining transcriptomics, epigenetics, and proteomics. Multiomics profiling studies enable a more comprehensive understanding of development, cellular response, and disease, fueling the discovery of novel drug targets and biomarkers. The progress our customers have made and what lies ahead inspire us to push the boundaries of what is possible so we can create the next generation of genomics solutions. At Illumina, our mission is to improve human health by unlocking the power of the genome. Our sequencing by synthesis chemistry is used to generate high-accuracy DNA and RNA sequence data in studies around the globe. Our microarrays provide accurate, high-throughput genotyping for a range of applications. The innovative products that we provide have already helped researchers make breakthroughs in many biological areas, including oncology, reproductive health, genetic disease, precision medicine, agriculture, microbiology, and beyond. The progress we see inspires us to push the boundaries of what is possible so we can create the next generation of genomics solutions.